Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
Othmane JadiiD, Hancong TangiD, Kelly Shea OlseniD, Steven P. Vensko IIiD, Qianqian ZhuiD, Yiwen WangiD, Christopher A. HaimaniD, Loreall PooleriD, Xin ShengiD, Guy Nathaniel BrockiD, Amy WebbiD, Marcelo C. PasquiniiD, Philip L. McCarthyiD, Stephen R. SpellmaniD, Theresa HahniD, Benjamin Garrett VincentiD, Paul M. ArmisteadiD, Lara E. Sucheston‐CampbelliD
Abstract
The role of minor histocompatibility antigens (mHAs) in mediating graft versus leukemia (GvL) and graft versus host disease (GvHD) following allogeneic hematopoietic cell transplantation (alloHCT) is recognized but not well-characterized. By implementing improved methods for mHA prediction in two large patient cohorts, this study aimed to comprehensively explore the role of mHAs in alloHCT by analyzing whether (1) the number of predicted mHAs, or (2) individual mHAs are associated with clinical outcomes using multi-variate survival models corrected for multiple testing. Cox proportional hazard results showed that patients with a class I mHA count greater than the population median had an increased hazard of GvHD mortality (HR=1.39, 95%CI 1.01, 1.77, P=0.046). Competing risk analyses identified the class I mHAs DLRCKYISL (gene GSTP), WEHGPTSLL (CRISPLD2) and STSPTTNVL (SERPINF2) were associated with increased GVHD death (HR=2.84, 95%CI 1.52, 5.31, P=0.01), decreased leukemia-free survival (LFS) (HR=1.94,95%CI 1.27, 2.95, P=0.044), and increased disease-related mortality (DRM) (HR=2.32, 95%CI 1.5, 3.6, P=0.008), respectively. One class II mHA YQEIAAIPSAGRERQ (TACC2) was associated with increased risk of treatment-related mortality (TRM) (HR=3.05, 95%CI 1.75, 5.31, P=0.02). WEHGPTSLL and STSPTTNVL were present in conjunction within HLA haplotype B*40:01-C*03:04 and showed a positive dose-response relationship with increased all-cause mortality and DRM and decreased LFS, indicating these two mHAs contribute to risk of mortality in an additive manner. Our study reports the first large scale investigation of the associations of predicted class I and class II mHA peptides with clinical outcomes following alloHCT. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=166 HEIGHT=200 SRC="FIGDIR/small/506092v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@1516a9aorg.highwire.dtl.DTLVardef@2db79aorg.highwire.dtl.DTLVardef@170e19aorg.highwire.dtl.DTLVardef@1eb7148_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
K. S. Olsen, O. Jadi, … B. Vincent·bioRxiv·Aug 12, 2022
- Predictive Modeling of acute Graft-versus-Host-Disease using Machine Learning on Immune Cell and Cytokine Profiles at Engraftment
Mohini Mendiratta, Praful Pandey, … Ranjit Kumar Sahoo·bioRxiv·Mar 13, 2025
- Use of human AML cells to study graft-versus-leukemia immunity in xenogeneic mouse models of GVHD
Charline Faville, Bianca E Silva, … Grégory Ehx·Methods in molecular biologyPeer-reviewed·Jan 1, 2025
- Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation
Amy P. Webster, Simone Ecker, … Stephan Beck·Frontiers in GeneticsPeer-reviewed·Apr 3, 2024
- Secondary lymphoid organ endothelial cells prime alloreactive CD4+ T cells to trigger acute graft-versus-host disease
Haroon Shaikh, Pia Wittmann, … Andreas Beilhack·bioRxiv·Oct 7, 2025
- Single-cell mass cytometry maps the evolution of immune cell signatures predictive of acute graft-versus-host disease
James A. Aries, Sarah Charrot, … JEFF K. DAVIES·bioRxiv·Feb 26, 2025